Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Acq. announced
Intec Pharma Ltd. (NTEC) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/13/2021 15-12B Form 15-12B - Securities registration termination [Section 12(b)]:
08/06/2021 8-K Quarterly results
08/03/2021 25-NSE Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities:
07/29/2021 425 Form 425 - Prospectuses and communications, business combinations:
07/29/2021 8-K Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta...
Docs: "Intec Announces $30 Million Private Placement Ahead of Decoy Merger"
07/23/2021 425 Form 425 - Prospectuses and communications, business combinations:
07/23/2021 8-K Other Events  Interactive Data
07/16/2021 425 Form 425 - Prospectuses and communications, business combinations:
07/16/2021 8-K Other Events  Interactive Data
06/22/2021 425 Form 425 - Prospectuses and communications, business combinations:
06/22/2021 8-K Quarterly results
05/17/2021 10-Q Quarterly Report for the period ended March 31, 2021
05/17/2021 EFFECT Form EFFECT - Notice of Effectiveness:
05/14/2021 DEFM14A Form DEFM14A - Definitive proxy statement relating to merger or acquisition:
05/12/2021 S-4/A Form S-4/A - Registration of securities, business combinations: [Amend]
04/30/2021 8-K Acquisition/merger/asset purchase announced
Docs: "AGREEMENT AND PLAN OF MERGER AGREEMENT AND PLAN OF MERGER, dated as of April 27, 2021, by and between Intec Pharma Ltd., an Israeli company , Intec Parent, Inc., a Delaware corporation and Domestication Merger Sub Ltd., an Israeli company and a wholly-owned subsidiary of Intec Parent , all having their registered offices in 12 Hartom Street Har Hotzvim, Jerusalem, 9777512 Israel. Intec Israel, Intec Parent and Domestication Merger Sub are each referred to herein as a “Party” and collectively as the “Parties”."
04/30/2021 425 Form 425 - Prospectuses and communications, business combinations:
04/20/2021 S-4 Form S-4 - Registration of securities, business combinations:
03/17/2021 10-K/A Annual Report for the period ended December 31, 2020 [amend]
03/16/2021 GN Intec Pharma Announces Filing of 2020 Annual Report on Form 10-K
03/16/2021 10-K Annual Report for the period ended December 31, 2020
03/15/2021 8-K Quarterly results
03/15/2021 425 Form 425 - Prospectuses and communications, business combinations:
02/16/2021 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/08/2021 8-K Quarterly results
01/29/2021 SC 13G/A INTRACOASTAL CAPITAL, LLC reports a 6.3% stake in Intec Pharma Ltd.
01/04/2021 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
12/09/2020 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Intec Pharma Announces Cannabinoid Research Collaboration with GW Pharma JERUSALEM - Intec Pharma Ltd. today announces it has entered into a feasibility agreement with GW Research Limited , London, U.K. to explore using the Accordion Pill platform for an undisclosed research program. “We are very excited to collaborate with GW,” said Jeffrey A. Meckler, Vice Chairman and Chief Executive Officer of Intec Pharma. “Through partnerships such as this, we continue to evaluate the utility of our Accordion Pill platform in the development of innovative therapeutics.” Additional details of the agreement were not disclosed. Intec Pharma is a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology. The Company’ s Accordion Pill..."
11/05/2020 10-Q Quarterly Report for the period ended September 30, 2020
11/05/2020 8-K Quarterly results
Docs: "Intec Pharma Reports Third Quarter 2020 Financial Results and Provides Corporate Update JERUSALEM - Intec Pharma Ltd. today announces financial results for the third quarter ended September 30, 2020 and provides a corporate update. “We maintain our focus on executing strategic partnerships and collaborations. As such, we were delighted in recent weeks to announce a new research collaboration with Merck. While we are unable to provide the specifics of the agreement, it speaks to Merck’ s keen understanding of the Accordion Pill technology and their continued interest in working with us to realize its potential,” stated Jeffrey A. Meckler, Vice Chairman and Chief Executive Officer of Intec Pharma. “In addition, we continue to innovate and progress our next generation gastric retentive techn..."
11/04/2020 SC 13G/A MEITAV DASH INVESTMENTS LTD reports a 3.1% stake in INTEC PHARMA LTD
10/29/2020 8-K Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea...
Docs: "ARTICLES OF ASSOCIATION, AS AMENDED ON OCTOBER 29, 2020",
"Intec Pharma Announces 1-for-20 Reverse Share Split JERUSALEM - Intec Pharma Ltd. today announces a 1-for-20 reverse share split of its outstanding ordinary shares. The reverse share split is scheduled to become effective after trading closes on October 29, 2020, and the Company’ s ordinary shares will begin trading on a split-adjusted basis on the Nasdaq Capital Market at the commencement of trading on October 30, 2020 under the Company’ s existing symbol “NTEC.” The Company’ s ordinary shares have been assigned a new CUSIP number of M53644148 in connection with the reverse share split. As previously disclosed, at the Company’ s Annual Meeting of Shareholders held on July 15, 2020, the Company's shareholders approved a proposal to amend the Company’ s Articles of Association to effect a ..."
10/08/2020 8-K Quarterly results
10/02/2020 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy